Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m.

Talawar Therapeutics will use the funds to take its AD (eczema) bispecific, TALA-125, through to Phase IIb proof-of-concept trials.

Anixa Biosciences has secured patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology.

Experts at HLTH Europe 2026 agreed that healthcare innovations won't meet their full potential until healthcare services can implement them.

The European Medicines Agency (EMA) has recommended that marketing authorisation for Tavneos (avacopan) be revoked due to a question mark over the integrity of clinical data used to support its ...

Biogen plans to pause or terminate investment in most of Apellis’ legacy research programmes, while cutting some of its workforce.